The present invention provides methods and compositions for the prophylactic or targeted prophylactic treatment of migraine. In one embodiment a patient is regularly given a therapeutically effective amount of a combination of a cyclooxygenase-2 inhibitor and acetylsalicylic acid or active derivative, for prophylactic treatment of migraine. In another embodiment, a patient, at a time prior to a determined time window, is administered a therapeutically effective amount of a cyclooxygenase-2 inhib...

The invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.

FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biopolymers that can find application in chemical-pharmaceutical industry, medicine and veterinary science. The complex of pectin biopolymer and acetylsalicylic acid of formulawherein R=H, Me

A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.

A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benori...